- Conditions
- Small Cell Lung Cancer
- Interventions
- Veliparib, Carboplatin, Etoposide, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Atlanta, Georgia + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 4,379
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Interventions
- Reduced Dose of Chemotherapy and Immunotherapy
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 2
- States / cities
- Richmond, Virginia • Tappahannock, Virginia
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin, Etoposide
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Daphne, Alabama • Hot Springs, Arkansas • Fort Myers, Florida + 17 more
- Conditions
- Neoplasms
- Interventions
- VIP236 (Q3W), VIP236 (Q2W)
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Cetuximab, Bevacizumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 43
- States / cities
- Decatur, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 39 more
- Conditions
- Solid Tumors and Hematologic Malignancy
- Interventions
- INCB054329 Monotherapy
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Advanced Nonsmall Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- Afatinib, Necitumumab, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Stanford, California • Nashville, Tennessee
- Conditions
- Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
- Interventions
- Lenalidomide, Pembrolizumab
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pleural Mesothelioma, Non-small Cell Lung Cancer
- Interventions
- THOR-707, Pembrolizumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- SGN-15, Docetaxel
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Portland, Oregon
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- CB-839, Nivolumab
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer
- Interventions
- Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, TLR8 Agonist VTX-2337
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- InVisionFirst-Lung ctDNA assay
- Diagnostic Test
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia
- Conditions
- Lung Cancer - Non Small Cell
- Interventions
- Ipilimumab, Pemetrexed
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Greenbrae, California • Galesburg, Illinois • Quincy, Illinois + 4 more
- Conditions
- Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 30
- States / cities
- Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 23 more
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- IOV-4001
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Rociletinib
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 41
- States / cities
- Alhambra, California • Bakersfield, California • Fullerton, California + 36 more
- Conditions
- Squamous Cell Carcinoma, Non-Small-Cell Lung
- Interventions
- Abraxane (Induction), Carboplatin (Induction), Abraxane (Maintenance), Best Supportive Care (Maintenance)
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 91
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more
- Conditions
- Solid Tumors
- Interventions
- Docetaxel, vantictumab
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Buffalo, New York • Cleveland, Ohio
- Conditions
- Lung Neoplasms, Second Primary Lung Cancer (SPLC), Non-Small Cell Lung Cancer (NSCLC), Stage I-IIIA, Lung Cancer (Diagnosis)
- Interventions
- Not listed
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Not listed
- Enrollment
- 1,826 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- figitumumab, Cisplatin (Or Carboplatin), Etoposide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 34
- States / cities
- Washington D.C., District of Columbia • Marrero, Louisiana • Metairie, Louisiana + 28 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, etoposide, ifosfamide, topotecan hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Lung Cancer, Pulmonary Complications
- Interventions
- educational intervention, supervised exercise program
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 60
- States / cities
- Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more